336 related articles for article (PubMed ID: 25431338)
1. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
2. The combined use of Camellia sinensis and metronomic zoledronate in 4T1 mouse carcinoma against tumor growth and metastasis.
Luo KW; Yue GG; Ko CH; Gao S; Lee JK; Li G; Fung KP; Leung PC; Lau CB
Oncol Rep; 2015 Jul; 34(1):477-87. PubMed ID: 25998578
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models.
Luo KW; Ko CH; Yue GG; Lee MY; Siu WS; Lee JK; Shum WT; Fung KP; Leung PC; Li G; Evdokiou A; Lau CB
Cancer Lett; 2013 Oct; 339(1):42-8. PubMed ID: 23896464
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the combined use of metronomic zoledronic acid and Coriolus versicolor in intratibial breast cancer mouse model.
Ko CH; Yue GG; Gao S; Luo KW; Siu WS; Shum WT; Shiu HT; Lee JK; Li G; Leung PC; Evdokiou A; Lau CB
J Ethnopharmacol; 2017 May; 204():77-85. PubMed ID: 28412218
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
7. Green tea (Camellia sinensis) extract inhibits both the metastasis and osteolytic components of mammary cancer 4T1 lesions in mice.
Luo KW; Ko CH; Yue GG; Lee JK; Li KK; Lee M; Li G; Fung KP; Leung PC; Lau CB
J Nutr Biochem; 2014 Apr; 25(4):395-403. PubMed ID: 24561153
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
10. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR
Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
Labrinidis A; Hay S; Liapis V; Ponomarev V; Findlay DM; Evdokiou A
Clin Cancer Res; 2009 May; 15(10):3451-61. PubMed ID: 19401351
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Wright LE; Harhash AA; Kozlow WM; Waning DL; Regan JN; She Y; John SK; Murthy S; Niewolna M; Marks AR; Mohammad KS; Guise TA
Oncotarget; 2017 Jan; 8(5):8406-8419. PubMed ID: 28039445
[TBL] [Abstract][Full Text] [Related]
13. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
[TBL] [Abstract][Full Text] [Related]
15. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
Labrinidis A; Hay S; Liapis V; Findlay DM; Evdokiou A
Int J Cancer; 2010 Jul; 127(2):345-54. PubMed ID: 19924813
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
Odri G; Kim PP; Lamoureux F; Charrier C; Battaglia S; Amiaud J; Heymann D; Gouin F; Redini F
BMC Cancer; 2014 Mar; 14():169. PubMed ID: 24612486
[TBL] [Abstract][Full Text] [Related]
18. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence-guided surgery of prostate cancer bone metastasis.
Miwa S; Matsumoto Y; Hiroshima Y; Yano S; Uehara F; Yamamoto M; Zhang Y; Kimura H; Hayashi K; Yamamoto N; Bouvet M; Sugimoto N; Tsuchiya H; Hoffman RM
J Surg Res; 2014 Nov; 192(1):124-33. PubMed ID: 24972740
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.
Misso G; Porru M; Stoppacciaro A; Castellano M; De Cicco F; Leonetti C; Santini D; Caraglia M
Cancer Biol Ther; 2012 Dec; 13(14):1491-500. PubMed ID: 22990205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
